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Abstract 
Background: The administration of supplemental oxygen to treat ventilatory insufficiency may lead to the formation 
of reactive oxygen species and subsequent tissue damage. Cytochrome P4501A1 (CYP1A1) can modulate hyperoxic 
lung injury by a currently unknown mechanism. Our objective was to evaluate the effect of administration of omepra-
zole on the induction of CYP1A1 and its influence on hyperoxic lung injury in an established preterm rabbit model.
Methods: Omeprazole was administered either (1) directly to the fetus, (2) to the mother or (3) after birth to the 
pups in different doses (2–10 or 20 mg/kg). Controls were injected with the same amount of saline. Pups were housed 
in normoxia (21 %) or hyperoxia (>95 %) for 5 days. Outcome parameters were induction of CYP1A1 measured by 
real-time polymerase chain reaction (RT-PCR) immediately after delivery, at day 3 and day 5 as well as lung function, 
morphometry and immunohistochemistry assessed at day 5 of life. Transcriptome analysis was used to define the 
targeted pathways.
Results: Daily neonatal injections demonstrated a dose-dependent increase in CYP1A1. Lung function tests showed 
a significant improvement in tissue damping, tissue elasticity, total lung capacity, static compliance and elastance. 
Morphometry revealed a more developed lung architecture with thinned septae in animals treated with the highest 
dose (20 mg/kg) of omeprazole. Surfactant protein B, vascular endothelial growth factor and its receptor were signifi-
cantly increased on immunohistochemical stainings after omeprazole treatment.
Conclusions: Neonatal administration of omeprazole induces CYP1A1 in a dose-dependent matter and combined 
pre- and postnatal administration attenuates hyperoxic lung injury in preterm rabbits, even with the lowest dose of 
omeprazole without clear CYP1A1 induction.
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Background
Although the incidence of preterm birth is decreasing 
slightly over the last years, it still affects 12  % of preg-
nancies in the United States [1]. In other countries, like 
Belgium, the preterm delivery rate may be lower (7.6  % 
deliveries <37 weeks), though remains stable. Severe pre-
maturity can affect many organ systems but respiratory 
insufficiency remains the major contributor to perinatal 
morbidity and mortality. The use of supplemental oxygen 
can be life-saving in preterm infants, but may also cause 
bronchopulmonary dysplasia (BPD). BPD is a multi-
organ disorder, which affects up to 50 % of extremely low 
birth weight infants <1000 g [2]. Survivors with BPD are 
at increased risk for readmission during the 1st year of 
life, long-term pulmonary problems and abnormal neu-
rodevelopmental outcome compared to those without 
BPD [3].
The use of excessive oxygen may lead to an increased 
production of reactive oxygen species (ROS) such as 
superoxide anion, hydroxyl radical and hydrogen perox-
ide [4–6] as well as the expression of pro-inflammatory 
cytokines [7]. ROS can oxidate or peroxide molecules like 
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structure or function [8]. Hyperoxia-induced produc-
tion of ROS is recognized as a major contributor to the 
development of BPD [9] because the tissue damage and 
inflammation leads to a developmental arrest of the lung.
In recent years, the importance of cytochrome P450 
enzymes as well as the aryl hydrocarbon receptor (AhR) 
has been demonstrated in the metabolism of a number 
of endogenous and exogenous compounds as well as for 
oxygen-induced toxicity [10–13]. When a ligand binds, 
AhR is translocated to the nucleus, where it dimerizes 
with the aryl hydrocarbon nuclear translocator (ARNT). 
This complex can thereafter bind to aryl hydrocardon 
reponse elements (AhRE) like the xenobiotic response 
elements (XRE) or dioxin reponse elements (DRE). Those 
response elements function as a cis-acting enhancer in 
the regulatory domains of genes known as the AhR gene 
battery. Included in this gene battery are many phase 
I and phase II detoxification enzymes like CYP1A1, 
CYP1A2, glutathione S-transferase-alpha, NAD(P)
H-quinone reductase-1, UDP-glucuronosyl transferase 
and aldehyde dehydrogenase [8]. The cytochrome P450 
enzymes are a superfamily of heme-containing pro-
teins that are involved in the metabolism of a number of 
endogenous and exogenous compounds [14]. CYP1A1 
is typically induced by planar aromatic hydrocarbons 
(PAH), but hyperoxia can also induce CYP1A1 [10, 15]. 
The exact mechanism of induction is unknown, but the 
AhR seems to play an important role as AhR [10, 12, 13] 
or CYP1A1 [16] deficient mice react differently on hyper-
oxic exposure. The induction by hyperoxia decreases if it 
continues for over 60 h in adult mice models [4, 17].
It has been suggested that CYP1A1 may modulate 
hyperoxic lung injury by scavenging of the ROS. Possible 
inducers besides PAH are beta-naphthoflavone (BNF) or 
3-methylcholanthrene (3-MC). Also omeprazole (OM) 
induces CYP1A1 possibly through an AhR-mediated pro-
cess. Omeprazole does not have the structural features 
of a typical AhR-ligand [18] and does not seem to bind 
AhR in a classical way [19, 20]. Possible explanations of 
transcription of CYP1A1 after administration of omepra-
zole are the decrease of the interaction forces which keep 
the AhR complex in a silencing state and thus a trans-
formation of the AhR into a DNA binding form [19]. A 
nuclear accumulation of a DNA-binding form of the AhR 
activates CYP1A1 transcription [19]. Also, omeprazole 
seems to activate CYP1A1 transcription through com-
mon regulatory regions as typical AhR ligands [21].
Omeprazole is a proton-pump inhibitor, which is 
widely used to treat gastro-oesophageal reflux disease 
or gastric ulcers by inhibition of gastric acid secretion 
in both humans and animals. It is plasma-protein bound 
for 97  % and is metabolized through the CYP2C19 and 
CYP1A4. The half-life is less than 1  h in humans, and 
elimination occurs renal for 80 %. The drug is approved 
for administration to infants and neonates as well as 
pregnant women [22]. Transplacental transfer is present 
but low, and dependent on the maternal plasma levels 
[23]. To our knowledge the use of omeprazole in prevent-
ing hyperoxia induced lung injury has only been dem-
onstrated so far in vitro [24] and in in vivo mice models 
[12, 25]. Herein, we test the hypothesis that in a hyper-
oxic induced lung injury preterm rabbit model, prenatal 
or neonatal administration of omeprazole (1) induces 
transcription of CYP1A1 in a dose-dependent way and 
(2) improves pulmonary outcome both on histological 
as well as functional level. In addition, we performed 
an unbiased pulmonary transcriptome analysis by RNA 
sequencing to assess the pathways targeted by omepra-
zole to explore its mechanism of action. We used our 
previously described model [26] of preterm rabbit pups 
exposed to hyperoxia to assess the induction of CYP1A1 
as well as the functional outcome parameters.
Methods
Animal protocol
All experiments were approved by the Ethics commit-
tee for Animal Experimentation of the Faculty of Medi-
cine of the KU Leuven. Animals were treated according 
to current guidelines of animal well-being. Time-mated 
pregnant does (hybrid of New Zealand White and Den-
dermonde) were obtained from the animalium of the KU 
Leuven. All does were housed in separate cages prior to 
an intervention or the cesarean section with a light–dark 
cycle of 12 h, a normal room temperature and free access 
to water and chow.
The first animals were used for a dose-finding study in 
which different administration routes, time points and 
doses of omeprazole were used to assess induction of 
CYP1A1 in the lung tissue. In the following animals both 
lung function as well as histological analysis were ana-
lyzed after pre- and postnatal administration of three dif-
ferent doses of omeprazole.
For the prenatal fetal injections (dose finding study), 
the doe was anesthetized with an intra-muscular injec-
tion consisting of a mixture of ketamin 35 mg/kg (Keta-
min 1000®; CEVA Sante Animale, Libourne, France) 
and xylazine 6 mg/kg (Vexylan®; CEVA Sante Animale). 
Anesthesia was maintained using a facemask with iso-
flurane 1.5–2  % (Isoba®Vet; Abbott Laboratories Ltd., 
Queenborough, Kent, UK) in oxygen at 2  L/min. Does 
received a single subcutaneous injection with penicil-
lin G 300.000  IU (Kela Pharma, Hoogstraten, Belgium), 
medroxyprogesterone acetate 0.9  mg/kg (Depo-Provera, 
Pharmacia Upjohn, Puurs, Belgium) and buprenorphine 
0.03 mg/kg (Vetergesic, Alstoe Limited, York, UK) before 
the surgical procedure. Surgery was performed in sterile 
Page 3 of 13Richter et al. J Transl Med  (2016) 14:247 
conditions with the rabbit positioned in a supine position 
on a heating pad. A midline laparotomy was used to exte-
riorize the uterine horns and thereafter the fetal umbili-
cal vein was punctured with a 24  G needle (Terumo® 
Surflo® Winged IV catheters, Terumo Europe, Leuven, 
Belgium) under ultrasound guidance (VEVO® 2100 sys-
tem, Visualsonic, Toronto, Canada) to inject the fetus. To 
minimize the risks for miscarriage, maximum six fetuses 
per doe were injected.
For the maternal injections (dose finding as well as 
functional outcome study), the doe was anaesthetized 
with an intra-muscular injection of ketamine (35 mg/kg) 
and xylazine (6 mg/kg) where after the marginal ear vein 
was punctured to inject omeprazole or saline.
To deliver the pups, a cesarean section was performed 
at day 28 of gestation (term  =  31  days) as previously 
described [26]. The pups used for the dose finding study 
at time point 0 were immediately euthanized with an 
intraperitoneal injection of T61® before the first breath 
and the lungs were removed and snap frozen for deter-
mination of CYP1A1 levels. All other pups were placed in 
an incubator (Dräger Incubator 7310, Dräger®, Lübeck, 
Germany) at 32 °C in either normoxia (21 % O2) or hyper-
oxia (>95 % O2). Pups were fed twice daily with a mixture 
of special formula milk containing 30 % of proteins and 
50  % of lipids (FoxValley 30/50, Illinois, US), Bio-Lapis 
for electrolytes, vitamins and probiotics (Protexin Vet-
erinary, Somerset, UK) and Col-o-cat with a high amount 
of immunoglobulins (Sanobest, ‘s Hertogenbosch, Neth-
erlands). The amount of feeding increased daily as pre-
viously described in detail [26]. Pups were daily injected 
with prophylactic antibiotics (penicillin and amikacine) 
from day 2 onwards [26]. Furthermore, daily intraperi-
toneal injections with placebo (=saline) or omeprazole 
were performed.
Pups were harvested immediately after delivery, at day 




Fifteen does (65 pups) were used for pre- or postnatal 
maternal, fetal and neonatal injections of omeprazole to 
assess the level of induction of CYP1A1 (Table 1).
  •  Fetal injections: fetuses were administered omepra-
zole into the umbilical vein under ultrasound guidance 
at 2 different time points (day 26 or day 27 of gesta-
tion, = 24 or 48 h prior to delivery) and with 2 different 
doses of omeprazole (low = 2 mg/kg or high = 20 mg/
kg). The dose was calculated with an estimated fetal 
weight described by our group previously [27]. This 
generated four groups, with a minimum of six pups per 
group (−48 h low/−48 h high/−24 h low/−24 h high). 
All injected pups were harvested by cesarean section at 
day 28 of gestation for immediate preservation of lung 
tissue.
  •  Prenatal maternal injections: under anesthesia other 
does were injected with omeprazole (low dose: 2 mg/
kg) in the marginal ear vein 48, 24 or 8 h prior to deliv-
ery. All their pups (minimum 7) were harvested imme-
diately after delivery.
  •  Neonatal injections: Pups held in hyperoxia were once 
daily injected intraperitoneally with one of three dif-
ferent doses of omeprazole (low: 2  mg/kg; medium: 
10  mg/kg; high: 20  mg/kg) starting immediately after 
delivery. Lungs were harvested at day 3 and 5. Pups 
housed in normoxia were only injected with the high-
est dose of omeprazole (=20 mg/kg/day).
Control animals were injected with a similar amount of 
saline and harvested at the same time points as treated 
animals. Untouched animals harvested immediately after 
delivery were used as the control group normalized to 1.
Functional assessment
Fifteen does (96 pups) were used for the assessment of 
lung function and histology (morphometry and immuno-
histochemistry) at day 5 of life Omeprazole was adminis-
tered prenatally to the doe (2 mg/kg) in combination with 
daily neonatal intraperitoneal injections (low: 2  mg/kg, 
medium 10 mg/kg and high 20 mg/kg) to the pups held 
in hyperoxia. Control animals were injected the same 
amount of saline. This lead to the following groups: (1) 
saline-injected, housed in normoxia (normo-saline); (2) 
saline-injected, housed in hyperoxia (hyper-saline); (3) 
low dose of omeprazole, housed in hyperoxia (hyper-
OMLow); (4) medium dose of omeprazole, housed in 
hyperoxia (hyper-OMmed) and finally (5) high dose of 
Table 1 Dose finding study
Administration Injections Harvest
Fetal −48 h saline −48 h OM low −48 h OM high −24 h saline −24 h OM low −24 h OM high At delivery
Maternal −48 h saline −48 h OM low −24 h saline −24 h OMlow −8 h saline −8 h OM low At delivery
Neonatal Daily saline (nor-
moxia)




Daily OM low 
(hyperoxia)
Daily OM med 
(hyperoxia)
Daily OM high 
(hypreoxia)
Day 3 –day 5
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omeprazole, housed in hyperoxia (hyper-OMhigh). Sur-
vival of the pups was assessed on a daily basis.
Quantification of CYP1A1 expression
Total RNA from freshly harvested and snap frozen lungs 
was isolated using TriPure Isolation Reagent (Roche 
Diagnostics, Vilvoorde, Belgium) according to the manu-
facturer’s guidelines. A maximum of 100  mg tissue was 
used per sample. The concentration was evaluated with 
NanoDrop ND-10000 spectrophotometer (NanoDrop 
Technologies, Wilmington, US). RNA was reversed tran-
scribed to cDNA using TaqMan Reverse Transcription 
Reagents (Applied Biosystems, Gent, Belgium). Real-time 
quantitative PCR analysis was performed with an ABI 
Prism 7000 detection system (Applied Biosystems) using 
Platinum SYBR Green qPCR Supermix-UDG (Invitrogen 
Life Technologies, Gent, Belgium). Primers were obtained 
from Integrated DNA Technologies (IDT, Heverlee, Beg-
lium) and Actin beta (ActB) was used as a housekeeping 
gene to normalize mRNA levels. The following primer 
sequences were: FWD 5′- GCACCGCAAGTGCTTCTA 
-3′ and REV 5′- GCCAATCTCGTCTCGTTTCT -3′ for 
ActB and FWD 5′- CATCTGTGCCATGTGCTTTG -3′ 
and REV 5′- TAGCGGAGGATGAGGAAGAA -3′ for 
CYP1A1. The relative mRNA levels for CYP1A1 were 
normalized to their ActB content. The ΔΔCt method 
was used to calculate the fold change in mRNA expres-
sion, where ΔCt = Ct(CYP1A1 gene)−Ct(ActB gene) and ΔΔCt =  
ΔCt (Omeprazole)−ΔCt(saline); fold change = 2(−ΔΔCt).
Lung function testing
Pups were anesthetized with ketamine (35  mg/kg) and 
xylazin (6  mg/kg) as previously described [26]. A Flex-
iVent analysis [28], an invasive measurement which is 
the gold standard for lung function testing in  vivo, was 
performed on anesthetized pups and the following 
parameters were assessed: airway resistance (Rn), tissue 
damping (resistance, G) and tissue elasticity (H) using 
Primewave-8 forced oscillation and the total lung capac-
ity (A), static compliance (Cst) and static elastance (Est) 
using the pressure–volume perturbation. All measure-
ments were performed until three consistent measure-
ments were obtained, with a coefficient of determination 
of >0.95 as the limit to accept the measurement. The 
average of these three measurements was calculated for 
further reporting. After the measurements, pups were 
euthanized using an intracardiac injection of 0.1  mL of 
T61®.
Morphometry
After lung function assessment, pups were euthanized, 
a thoracotomy was performed to remove the lungs and 
trachea ‘en bloc’. The left bronchus was ligated follow-
ing which the left lung was removed and snap frozen for 
determination of CYP1A1 levels. A 20G catheter was 
inserted into the trachea to pressure-fix the right lung 
with 4  % paraformaldehyde by immersion and a con-
stant hydrostatic pressure of 25 cm H2O for 24 h. After 
embedding, 5  µm paraffin sections were stained with 
hematoxylin and eosin (HE). Morphometric measure-
ments consisted of (1) the linear intercept (Lm), which is 
a measure of alveolar size, (2) the mean terminal bron-
chiolar density (MTBD) which is inversely correlated to 
the number of alveoli supplied by each bronchiole and 
finally (3) the mean wall transection length (Lmw), a 
measure of the interalveolar septal thickness [29]. Vas-
cular morphometry was performed on sections stained 
with Miller’s elastic staining of lungs harvested in pups 
held in normoxia, or in hyperoxia treated with saline or 
OMhigh. The external diameter and internal diameter 
were measured along the shortest axis of peripheral mus-
cularized vessels with less than 100 µm external diameter. 
These parameters were used to calculate the proportion-
ate medial thickness (% MT = ED−ID/ED × 100) as pre-
viously described [29].
Immunohistochemistry
Immunohistochemical staining was performed for sur-
factant protein B (SP-B) to determine airway maturity 
and for vascular endothelial growth factor (VEGF) and 
its receptor fetal liver kinase 1 (Flk-1) to assess vascu-
lar markers of lung maturity. Slides were incubated with 
(1) goat anti-mouse polyclonal anti-SP-B (Santa Cruz 
Biotechnology, Heidelberg, Germany), (2) mouse anti-
human monoclonal anti-VEGF (NeoMarkers, Fremont, 
CA, US) and finally (3) mouse anti-human monoclonal 
anti-Flk-1 (Santa Cruz Biotechnology). Secondary anti-
body incubation for SP-B slides was mouse anti-goat bio-
tin (Santa Cruz Biotechnology) plus normal rabbit serum 
(DakoCytomation) followed by rinsing and incubation 
with streptavidin alkaline phosphatase (Roche Diagnos-
tics, Vilvoorde, Belgium), rinsing, incubation with NBT 
solution and counterstaining with Methyl green (Dako-
Cytomation). After rinsing the slides stained for VEGF 
and Flk-1 they were incubated with peroxidase-conju-
gated EnVisionTM and reagent (DakoCytomation), rinsed 
with PBS, incubated with peroxidase substrate solution 
containing DAB, rinsed with distilled water, counter-
stained with hematoxylin, dehydrated and mounted. 
Quantification of positive cells was performed semi-auto-
matically using ImageJ software (1.47v, NIH, Bethesda, 
Maryland, USA). Ten random images from each slide 
were processed using the Axioskop platform (Carl Zeiss, 
Oberkochen, Germany).
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Transcriptome analysis and validation RT‑PCR
Transcriptome analysis was done on snap frozen whole 
left lungs of four saline- and four omeprazole-treated 
(high dose) rabbits held in hyperoxia. Snap frozen whole 
left lungs were homogenized using the TissueLyser (Qia-
gen) and total RNA was isolated with the RNeasy mini-
kit (Qiagen), RNA concentration was measured using 
the Nanodrop 1000 spectrophotometer (Thermo Sci-
entific) and RNA integrity was assessed using the RNA 
6000 Nano Kit and the Bioanalyser (Agilent Technolo-
gies). mRNA isolation, cDNA conversion and sequenc-
ing library preparation was performed using the TruSeq 
RNA library preparation kit (Illumina). Fastq files were 
thereafter imported into Array Studio (Omicsoft) and 
mapped against the Ensembl reference rabbit genome 
and transcriptome (Build: Oryctolagus cuniculus.ory-
Cun2.64). Expression values were calculated per gene 
and normalized to ‘reads per kilobase per million reads’ 
(RPKM) values as described by Mortazavi [30]. Genes 
with an RPKM value of <1 in all samples were excluded. 
RPKM values were Log transformed for downstream 
analysis using the general linear model function in Array 
Studio for group comparison. Fold changes (FC) were 
calculated, indicating the ratio of change in gene expres-
sion. We applied a fold change cut-off of >1.5 or <−1.5, 
in order to filter out non-dysregulated molecules. Due 
to multiple testing, false discovery rates (FDR—Benja-
mini-Hochberg procedure) were calculated as a measure 
for statistical significance of the fold change difference 
observed between the two groups. We considered a tran-
script change significant if FDR was <0.05.
Further analysis was performed using the ingenu-
ity pathway analysis (IPA) software. The IPA ‘upstream 
regulator analysis’ (URA) predicts upstream regula-
tors by combining the directional expression changes 
from our mRNA-sequencing, and knowledge from prior 
experimental reports on causal effects between mol-
ecules (endogenous and exogenous), compiled in IPA 
Knowledge Base. URA calculates a z-score based on the 
edge of dysregulation of all the downstream molecules 
and the uniformity of the existing evidence about the 
upstream–downstream relation, for every upstream reg-
ulator known to have a causal effect on at least four dys-
regulated transcripts. Z-scores <−2 and >2 respectively 
predict a significant inhibition and activation state of the 
upstream regulator, regardless of the actual expression 
level of these molecules.
The fresh frozen lung tissue of those animals was 
furthermore used for RT-PCR analysis to validate 
three genes: CA4, SCGB1A1 and VEGF. To per-
form the analysis, the same methodology was used as 
described earlier, and ActB was used as housekeep-
ing gene. The primer sequences for the genes were: 
FWD 5′-GGAGTTCTCGAGCAAACTCTAC-3′ and 
REV 5′-CTGCGGCCTGTGACTTAAA-3′ for CA4; 
FW 5′-GATGCAGGGATGCAGATGAA-3′ and REV 
5′-CACAGTGGGCTCTTCACTATTT-3′ for SCGB1A1 
and FWD 5-ATCATGCGGATCAAACCTCA-3′ and 
REV 5′-CAAGGCCCACAGGGATTTTC-3′ for VEGF.
Statistical analysis
Kaplan–Meier curves with posthoc testing were used to 
quantify postnatal survival of rabbit pups using Graph-
Pad Prism 5.0 software (GraphPad, La Jolla, California, 
USA). For the dose finding study as well as immunohis-
tochemical and RT-PCR analysis, a Kruskal–Wallis test 
followed by Dunn’s multiple comparison test for post hoc 
analysis was performed.
All other parameters were assessed in a regression-
modeling framework, using PROC MIXED with the 
repeated statement in SAS (Statistical Analysis Software, 
Cary, USA). This method was chosen because several 
pups from the same doe were used, such that data are 
clustered, and the mother can be considered a random 
effect that is nested within the group. For those param-
eters, all three omeprazole exposed groups (low, med 
and high) were compared as a group against the saline 
treated animals held in normoxia and hyperoxia, and 
against each other to define significant changes. A value 
of p < 0.05 was considered statistically significant. All val-
ues are expressed as mean ± standard deviation.
Results
Omeprazole dose finding study
Direct fetal injections with omeprazole did not increase 
CYP1A1 expression as measured at delivery (data not 
shown). Increase in expression of CYP1A1 after a sin-
gle maternal dose of omeprazole (2 mg/kg IV) adminis-
tered 8 h prior to delivery (relative expression of CYP1A1 
1.139  ±  0.4105) did not reach statistical significance 
compared to controls (p = 0.872).
Daily neonatal injections in hyperoxia exposed 
pups showed a dose-dependent rise in expression of 
CYP1A1 (Fig.  1) both at postnatal day 3 and 5. The 
induction of CYP1A1 expression at day 3 was signifi-
cantly higher in pups treated with the medium and 
high OM dose compared to saline treated animals 
(p < 0.001 for both). This was not the case for the low 
dose of omeprazole (p  =  0.399). At day 5, the effect 
persisted, significant for the medium and high dose, 
yet less pronounced than on day 3 (p  =  0.022 and 
p = 0.002 resp.). In normoxic animals, the administra-
tion of omeprazole (high dose) showed a significant 
induction of CYP1A1 both on day 3 and 5 (p = 0.005 
and p  <  0.001 resp.). Furthermore, at day 5 the 
CYP1A1 expression in normoxic saline-treated pups 
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was significantly higher compared to hyperoxic saline 
treated pups (p = 0.027).
All further experiments were performed after a mater-
nal injection of saline or omeprazole (2  mg/kg IV) 8  h 
prior to delivery, and daily neonatal injections with either 
saline or omeprazole (low, med, high).
Effect of omeprazole on postnatal survival
Survival rates were 79.2 % (normo-saline), 57.6 % (hyper-
saline), 67.7  % (hyper-OMlow), 65.2  % (hyper-OMmed) 
and 82.1  % (hyper-OMhigh). These differences did not 
reach statistical significance (p = 0.229).
Omeprazole improves lung function
The results of the lung function tests are displayed in 
Fig.  2. There was no difference in the airway resist-
ance between the different groups. Hyperoxia exposure 
(hyper-saline) caused a significant increase in both tis-
sue damping and elasticity compared to normoxic con-
trols (p = 0.0011 and p = 0.0032 resp.). Administration 
of variable doses of omeprazole was associated with a 
decreased tissue damping as well as elasticity of pups 
exposed to hyperoxia compared to saline-treated con-
trols (p = 0.0007 and p = 0.0034 resp.). pressure–volume 
perturbation analysis revealed a significantly improved 
total lung capacity, static compliance and static elastance 
compared to saline treated animals held in hyperoxia 
(p < 0.001, p = 0.0001 and p = 0.0016 resp.)
Omeprazole attenuates prematurity induced 
lung‑developmental arrest
Morphometry results are displayed in Fig. 3. There were 
no significant differences between saline treated animals 
held in normoxia or hyperoxia for Lm (p = 0.83) neither 
MTBD (p = 0.23). Hyperoxia however did increase Lmw 
significantly (p  =  0.01). Comparing all treated animals 
together as one group against saline treated hyperoxic 
animals, no significant differences were found for Lm 
(p = 0.08), MTBD (p = 0.34), nor Lmw (p = 0.05). Again, 
there were significant differences for the highest dose of 
OM for Lm (p = 0.02) as well as Lmw (p = 0.03). There 
was no obvious effect on Lm and Lmw following admin-
istration of the low or medium dose.
The lungs of hyperoxic animals treated with the highest 
dose of omeprazole were thereafter compared with saline 
treated controls held in normoxia and hyperoxia. These 
results demonstrated a significant increase of the medial 
thickness of saline treated animals held in hyperoxia 
compared to normoxic controls. This effect was attenu-
ated after administration of omeprazole (p  =  0.007, 
Fig. 4).
The results of the immunohistochemical stains are 
shown in Fig. 5. There were no differences between both 
saline treated groups. Following administration of the 
medium and high dose of omeprazole, SP B, as well as 
VEGF and its receptor Flk-1 were significantly increased 
(p < 0.001 for all three). The lowest dose of omeprazole 
did not have an effect on any of the measured variables.
Transcriptome analysis
A total number of 315 transcripts were significantly dys-
regulated applying a filter on fold-change of >1.5 and 
<−1.5 with a FDR of <0.05. Expression data from all 315 
dysregulated genes are displayed in a heat map (Fig.  6) 
where color intensity reflects the Log2 transformed 
RPKM gene expression values. Of these 315 transcripts, 
Fig. 1 Induction of CYP1A1. Relative expression of CYP1A1 using the ΔΔCt method, measured by RT-PCR in freshly harvested lung tissue at day 3 
and day 5 of life. Animals held in normoxia (injected with saline or high dose of omeprazole) or housed in hyperoxia (injected with saline or low/
medium/high dose of omeprazole). Bars are mean ± SEM. *p < 0.05 compared to normoxia, saline treated. #p < 0.05 compared to hyperoxia, saline 
treated
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a
b
Fig. 2 Lung function tests using forced oscillation technique. a Primewave-8 measurement for Rn airway resistance, G tissue damping and H tissue 
elasticity. b Pressure–volume perturbation for A total lung capacity, Cst static compliance and Est static elastance. Animals housed in normoxia 
(injected with saline) or hyperoxia (injected with saline or low/medium/high dose of omeprazole) and harvested day 5. Bars are mean ± SEM. 
*p < 0.05 compared to normoxia, saline treated. #p < 0.05 compared to hyperoxia, saline treated
Fig. 3 Lung morphometry. Analysis of the Lm linear intercept, MTBD mean terminal bronchiolar density and Lmw mean wall transection length. 
Animals housed in normoxia (injected with saline) or hyperoxia (injected with saline or low/medium/high dose of omeprazole) and harvested day 
5. Bars are mean ± SEM, 1–5 HE staining of the right lung, animals held in normoxia (1), hyperoxia saline treated (2) or hyperoxia treated with a low 
(3), medium (4) or high (5) dose of omeprazole. *p < 0.05 compared to normoxia, saline treated. #p < 0.05 compared to hyperoxia, saline treated
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271 had known human homologues that are recognized 
by IPA. Further analysis was performed using these 271 
transcripts. Table  2 shows the 10 most up- and most 
down-regulated transcripts. The most upregulated gene 
in our dataset is CYP1A1 (FC 96,782; FDR 1,80 × 10−3), 
the most downregulated gene is PLEKHB2 (FC-55,950; 
FDR 3,79 × 10−2). By performing URA, we predict that 
13 endogenous and exogenous molecules (Table  3) are 
significant upstream regulators of the transcription 
changes observed in our dataset.
Based on current knowledge on the pathophysiologi-
cal mechanisms involved in BPD and hyperoxia induced 
lung injury, and by using the analysis tools in IPA, we 
identified several dysregulated molecules that potentially 
play a role in the observed beneficiary effect of omepra-
zole. We demonstrate that omeprazole affects molecules 
involved in inflammation, reactive oxygen species (ROS) 
metabolism, vascular growth and development, extracel-
lular matrix remodeling and lung development (Addi-
tional file 1: Table S1).
Validation RT-PCR was performed on lungs of saline-
treated animals held in normoxia and hyperoxia, and 
animals treated with high dose of omeprazole held in 
hyperoxia (Fig.  7). Three genes were examined, and all 
three were significantly downregulated after hyperoxic 
exposure (p =  0.023, p < 0.001 and p =  0.038 for CA4, 
SCGB1A1 and VEGF resp.), but only the increase of 
SCGB1A1 after treatment with omeprazole reached sta-
tistical significance.
Discussion
The principal aim of this study was to assess the effect of 
omeprazole treatment on hyperoxia induced lung toxicity 
in preterm rabbit lungs. Our central hypothesis was that 
Fig. 4 Vascular morphometry. vascular morphometry with the medial thickness (%MT) and Miller staining of a blood vessel <100 μm diameter; 
animals housed in normoxia (1), hyperoxia treated with saline (2) or hyperoxia treated with OM high (3). *p < 0.05 compared to normoxia, saline 
treated. #p < 0.05 compared to hyperoxia, saline treated
Fig. 5 Immunohistochemstry. Immunohistochemical staining for Flk-1, VEGF and SP-B performed on lung tissue harvested day 5 of life. Animals 
housed in normoxia (injected with saline) or hyperoxia (injected with saline or low/medium/high dose of omeprazole) and harvested day 5. Bars are 
mean ± SEM. *p < 0.05 compared to normoxia, saline treated. #p < 0.05 compared to hyperoxia, saline treated
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omeprazole attenuates the inflammatory and functional 
changes in the lung tissue, potentially through the induc-
tion of the cytochrome CYP1A1. This role of CYP1A1 
was demonstrated by Moorthy et  al. [5] in a study 
where rats were pretreated with an inhibitor of CYP1A1 
(1-aminobenzotriazole) with significant worsening of 
hyperoxic lung injury compared to controls [5]. Further-
more, recent studies have demonstrated an attenuating 
effect of CYP1A1 inducers on hyperoxic lung injury both 
in vitro [10, 24] as well as in vivo [11–13].
In the first part of our study, we analyzed the dose 
dependency of omeprazole induced CYP1A1 levels. Pre-
natal administration with the given doses, either directly 
(ultrasound guided fetal administration) or indirectly 
(maternal administration), failed to induce CYP1A1 
expression in the lung tissue at birth. This might be 
explained by the single injection used in all prenatal 
administrations. Postnatal administered omeprazole effi-
ciently and persistently (d3 and d5) increases the expres-
sion of CYP1A1 in pups exposed to normoxia. Hyperoxia 
has a pronounced effect on the efficiency of induction. In 
hyperoxia the increases were more modest and decreased 
over time (levels were around 45 and 5  % of what was 
observed in pups exposed to normoxia on day 3 and 5 
resp.). This less efficient and decreasing expression could 
be expected, as prolonged exposure to hyperoxia has 
been shown to decrease the expression of CYP1A1 in 
adult rats [4]. Our administration dosing and regimens 
were based on clinical practice and literature data. In 
infants omeprazole is usually given at 1–2  mg/kg/day, 
so the low dose reflects this current clinical regimen. 
Rodent data about the induction of CYP1A1 by omepra-
zole mention higher dosages (50  mg/kg/day, [12]). Shih 
Fig. 6 Heatmap. All transcripts with a fold change of >1.5 or <−1.5 
and false discovery rate of <0.05 are shown. Color intensity displayed 
in the heatmap are the Log2 transformed RPKM gene expression 
value. These are normalised to relative low (green) and high (red) sig-
nal intensities shown in the heatmap key. OM omeprazole, P placebo
Table 2 Most up- and down regulated transcripts in omeprazole treated animals
Name Full name FC FDR
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 96.782 1.80E−03
CA4 carbonic anhydrase IV 4.507 2.34E−02
S100A1 S100 calcium binding protein A1 3.081 2.87E−02
SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) 2.438 3.79E−02
ASB9 ankyrin repeat and SOCS box containing 9 2.326 2.22E−02
SRGN Serglycin 2.259 1.65E−02
PSMC3IP PSMC3 interacting protein (HOP2) 2.087 1.64E−02
UNC13D unc-13 homolog D (C. elegans) 2.059 4.59E−02
PTRHD1 peptidyl-tRNA hydrolase domain containing 1 1.967 4.00E−02
ID2 inhibitor of DNA binding 2, dominant negative helix-loop−helix protein 1.902 1.52E−02
PLEKHB2 pleckstrin homology domain containing, family B (evectins) member 2 −55.950 3.79E−02
S100A12 S100 calcium binding protein A12 −4.497 4.84E−02
CALB2 calbindin 2 −4.056 2.90E−02
KIF5C kinesin family member 5C −2.541 3.08E−02
ANO5 anoctamin 5 −2.428 1.10E−03
PAPPA pregnancy-associated plasma protein A, pappalysin 1 −2.416 1.33E−02
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 −2.352 4.97E−02
OMA1 OMA1 zinc metallopeptidase −2.188 4.22E−02
EDA2R ectodysplasin A2 receptor −2.119 3.75E−02
LIMA1 LIM domain and actin binding 1 −2.034 4.94E−02
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[31] described an obvious species specific range of induc-
tion of CYP1A1 by omeprazole.
After we established that omeprazole is an efficient 
CYP1A1 inducer, we set out to study the effect of ome-
prazole treatment on hyperoxia induced changes in 
preterm rabbit lungs. The exposure of rabbit lungs in 
the saccular stage of development to persistent high 
levels of oxygen (>95  %) leads to inflammatory changes 
and developmental arrest [26]. This becomes obvious 
in lung function testing by an increase in tissue damp-
ing and elasticity, a worsening in static compliance and 
elastance and a reduction in the total lung capacity. At 
the microscopic scale this corresponds to thickened sep-
tation and less developed alveoli. Omeprazole markedly 
attenuated all these functional changes already at the 
lowest dose without obvious dose dependency. Hyper-
oxia did not lead to changes in resistance in the conduct-
ing airways as the major pathological changes are taking 
place in the lung parenchyma.
This improved function would suggest a normalization 
of the parenchymal architecture. Indeed the mean wall 
transection length (Lmw), an index of the thickness of 
alveolar septae decreased to values that were comparable 
to lungs of pups kept in normoxic conditions, yet only for 
Table 3 Endogenous and  exogenous molecules predicted to  be upstream regulators of  the observed transcription 
changes
IPA Entrez gene name z‑score P of overlap
Upstream regulators predicted to be activated
 miR-155-5p (miRNAs w/seed UAAUGCU) microRNA 155-5p 2.611 2.08 × 10−3
 miR-16-5p (and other miRNAs w/seed AGCAGCA) microRNA 16-5p 2.425 2.58 × 10−2
 miR-30c-5p (and other miRNAs w/seed GUAAACA) microRNA 30c-5p 2.000 3.46 × 10−2
 MAPK9 mitogen-activated protein kinase 9 2.189 1.18 × 10−2
Upstream regulators predicted to be inhibited
 VEGF vascular endothelial growth factor (as a group) −2.229 1.23 × 10−3
 Gentamicin / −2.236 1.68 × 10−1
 STAT3 signal transducer and activator of transcription 3 −2.613 8.60 × 10−3
 EPAS1 endothelial PAS domain protein 1 −2.219 3.03 × 10−3
 NKX2-3 NK2 homeobox 3 −2.091 3.65 × 10−3
 ERG v-ets avian erythroblastosis virus E26 oncogene homologue −2.000 2.47 × 10−2
 OSM oncostatin M −2.687 7.06 × 10−4
 SP600125 / −2.236 5.61 × 10−2
 Lipopolysaccharide / −3.072 2.63 × 10−2
Fig. 7 validation RT-PCR. Fold changes of CA4, SCGB1A1 and VEGF using the ΔΔCt method, measured by RT-PCR in freshly harvested lung tissue 
at day 5 of life. Animals held in normoxia injected. with saline, or housed in hyperoxia (injected with saline or high dose of omeprazole). Bars are 
mean ± SEM. *p < 0.05 compared to normoxia, saline treated. #p < 0.05 compared to hyperoxia, saline treated
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the highest dose of omeprazole. The distal airway com-
plexity increased as well, evidenced by a smaller alveolar 
diameter (represented by Lm) but only in the cohort with 
the highest OM dose.
In order to analyze some possible effectors of this 
changes, we quantified the presence of surfactant protein 
B (a crude measure for lung maturation) and VEGF and 
one of its receptors Flk-1 (an important regulator dur-
ing lung development and angiogenesis). Treatment with 
omeprazole had a profound dose-dependent effect on all 
three factors.
As the rabbit is not an easy model to study up- and 
downstream effects (e.g. cytokine levels, immunologi-
cal changes, etc.) of oxygen toxicity due to the paucity 
of commercially available reagents, we also performed 
a transcriptome analysis. Herein we demonstrated that 
omeprazole affects molecules involved in inflamma-
tion, reactive oxygen species (ROS) metabolism, vascular 
growth and development, extracellular matrix remod-
eling and lung development. These processes are thought 
to be key features of hyperoxia induced lung injury and 
BPD [32]. However, apart from 1 publication on CA4 
in gastric mucosa [33], CYP1A1 is the only dysregu-
lated molecule in our dataset which has previously been 
related directly to omeprazole. Of course, based on our 
experiment, it is impossible to state whether the other 
observed gene changes are direct effects of omeprazole, 
or whether they are secondary changes due to an attenu-
ation of the oxidative stress by e.g. CYP1A1. The results 
of the validation RT-PCR did demonstrate a significant 
increase of SCGB1A1 after omeprazole treatment, no sig-
nificant changes were found for CA4 nor VEGF. Further 
mechanistic research needs to be performed to validate 
our transcriptome data, and to further elucidate the path-
ways involved in the beneficiary effect of omeprazole.
Other experiments already demonstrated that ome-
prazole modulates hyperoxia-induced lung pathology 
through induction of CYP1A1 [12, 24]. The importance of 
the CYP1A1 gene has been highlighted again in a recent 
study using CYP1A1 −/− mice which suggests a mecha-
nistic role for CYP1A1 [16]. Although there was a clear 
dose-dependent induction of CYP1A1 after daily admin-
istrations of omeprazole, the functional outcomes had no 
linear correlation with CYP1A1 level, as lung function 
improved even at the lowest dose of omeprazole. Several 
explanations are possible. Firstly, several in  vitro studies 
have demonstrated both the anti-inflammatory properties 
by inhibition of neutrophil function as well as anti-oxidant 
properties by direct scavenging activity against oxygen 
free radicals [34, 35]. Secondly, the induction of CYP1A1 
occurs through activation of the aryl hydrocarbon recep-
tor, as already demonstrated in multiple studies [10, 12, 13, 
24]. Activation of the AhR does not only act on CYP1A1 
but on a variety of molecules. The aryl hydrocarbon 
nuclear translocator (ARNT) is an important factor in 
the pathway of the hypoxia-inducible factors (HIF-1α and 
HIF-2α) as ARNT serves as a dimerization partner. Sta-
bilization of HIF might lead to an increased expression of 
growth factors for pulmonary alveolarization and angio-
genesis [36]. Furthermore, AhR is suggested to be a sup-
pressor of lung inflammation through its interaction with 
nuclear factor-κB as has been shown in studies evaluating 
cigarette smoke [37, 38] or influenza [39]. Recently Stock-
inger [40] reviewed the anti-inflammatory properties of 
AhR activation. Lung-resident dentritic cells seem to play 
an important role by modulating the immune-suppressive 
enzyme indolamine 2, 3 dioxygenase. Furthermore, AhR 
activation has an important effect on the differentiation of 
IL-17 producing T-helper cells, and bronchial fibroblasts 
who are sensitive to IL-17 can produce inflammatory 
mediators and chemoattractants such as IL-6 and IL-8 in 
response to IL-17 stimulation.
A recent study performed on neonatal mice has dem-
onstrated a potentiation of hyperoxia induced lung injury 
after administration of omeprazole [25]. These results are 
in conflict with our data, but several explanations are pos-
sible. First there is the difference in experimental animal, 
as Shih has demonstrated the important species differ-
ence in CYP1A1 induction [31]. Secondly, the study of 
Shivanna showed an increase in AhR after a short period 
(4 days), but this effect disappeared after 14 days of hyper-
oxic exposure. So there might be a time period in which 
omeprazole has a benefit that disappears when adminis-
tered for too long with even a toxic effect depending on 
dose and/or duration of treatment. A more recent study 
from the same research group has demonstrated that 
there is no potentiation of hyperoxia induced cell toxicity 
after administration of omeprazole [41]. This might again 
be explained by the shorter duration of hyperoxia and 
administration period of omeprazole, as well as the use of 
human pulmonary microvascular endothelial cells instead 
of rodents. More research is needed to address the most 
effective but also safe dose and duration of treatment, 
before this can be translated into human care.
We acknowledge a number of limitations to our study. 
First, though lung development of the rabbit is closer 
to that of man than rodents, it still differs compared to 
larger animals like baboons or sheep [42]. Another limi-
tation is the lack of data of normoxic animals treated with 
omeprazole, which in clinical practice would be a group 
not qualifying for treatment, but could have offered fur-
ther insides in the effects seen after administration of 
omeprazole. Furthermore, the high concentration of oxy-
gen (>95 %) and the relative short time interval of 5 days 
does not mimic entirely the human situation of what 
is referred to as the “new” BPD. In our previous model 
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[26] we used 7 days of hyperoxic exposure, but decided 
for a shorter duration in an attempt to decrease mortal-
ity. We are however working to expand this model with 
chronic exposure to oxygen. Studies with larger animals 
will be needed to assess efficacy of the lowest dose, and 
safety of higher doses of omeprazole in the prevention 
of hyperoxia induced lung injury as long term exposure 
to omeprazole might have negative effects on outcome 
[25]. Another limitation might be the combined used of 
pre- and postnatal administration of omeprazole with-
out assessing both independently. Possible side effects 
of gastric acid inhibitors used in preterm infants are the 
increased risk of bloodstream and respiratory infections 
and necrotizing enterocolitis [43] but these complica-
tions seem to occur more with the use of H2 antagonists 
rather than proton pump inhibitors like omeprazole [44].
The strengths of our study are the use of different doses 
of omeprazole administered through different admin-
istration routes, as well as the assessment of both lung 
function as well as histological parameters.
Conclusions
Postnatal administration of omeprazole induces CYP1A1 
expression in a dose-dependent manner and combined 
maternal and neonatal administration improves neona-
tal pulmonary lung function. This is paralleled by a more 
mature lung architecture in preterm rabbit pups exposed 
to hyperoxia. As the lowest dose of omeprazole had a 
positive effect on lung damage, without a clear increase 
of CYPA1A, further research will be necessary to eluci-
date the exact mechanism at which omeprazole attenu-
ates the hyperoxic lung injury.
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